Business
Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board
Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn’s disease, and late-stage clinical trial design Appointments strengthen Palisade Bio’s clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn’s disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the
About this update from Palisade Bio, Inc.
[{"type":"image","alt":"Palisade Bio, Inc.","displaySize":"","headline":null,"caption":"Palisade Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":77,"url":"https://media.zenfs.com/en/globenewswire.com/2a3a6d9c80425bf813c98abfe355e747"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VBDa4YPveOaoDW8bYlQJUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2a3a6d9c80425bf813c98abfe355e747","width":300,"height":77}},"lazy":false},{"type":"text","content":"Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn’s disease, and late-stage clinical trial design","length":168,"tagName":"p"},{"type":"text","content":"Appointments strengthen Palisade Bio’s clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn’s disease, with a Phase 2 UC IND submission planned for the first half of 2026","length":230,"tagName":"p"},{"type":"text","content":"Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced the appointment of Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, two internationally recognized leaders in inflammatory bowel disease (IBD), to its Clinical Advisory Board (“CAB”).","length":496,"tagName":"p"},{"type":"text","content":"“Professors Peyrin-Biroulet and Rubin are among the most influential voices in modern IBD medicine, each bringing extraordinary clinical insight, regulatory experience and scientific rigor to our Clinical Advisory Board,” said JD Finley, Chief Executive Officer of Palisade Bio. “Their complementary expertise across disease modification, fibrosis, treat-to-target strategies and trial execution will be invaluable as we advance PALI-2108 toward the clinic. Together with our existing advisors, their guidance will help position Palisade at the forefront of next-generation IBD therapeutics.”","length":592,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":160,"height":156,"...